Cstone pharma aktie
WebApr 23, 2024 · CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs ... WebCSTONE PHARMACEUTICALS REGISTERED AKTIE Profil - hier finden Sie alle Informationen über CSTONE PHARMACEUTICALS REGISTERED AKTIE wie z.B. Management, Profil, Aktionärsstruktur und Bilanzdaten.
Cstone pharma aktie
Did you know?
WebNov 22, 2024 · CStone Pharmaceuticals continues to expand its oncology presence aimed at the Chinese market. On Sunday, the company forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.. Currently, the only anti-CTLA-4 monoclonal antibody that … WebAlso Known As 基石药业, Jishi Yaoye. Legal Name CStone Pharmaceuticals Co., Ltd. Stock Symbol HKG:2616. Company Type For Profit. Contact Email [email protected]. Phone Number + 86- …
WebJan 4, 2024 · Cstone Pharmaceuticals has announced the U.S. Food and Drug Administration’s (FDA) STUDY MAY PROCEED (SMP) letter and investigational new drug (IND) application approval for CS5001, a … WebFunding. CStone Pharmaceuticals has raised a total of $410M in funding over 2 rounds. Their latest funding was raised on May 9, 2024 from a Series B round. CStone Pharmaceuticals is registered under the ticker HKG:2616 . Their stock opened with HK$12.00 in its Feb 25, 2024 IPO.
WebMay 28, 2024 · Shanghai - CStone Pharmaceuticals Co., Ltd. ('CStone' or the 'Company', HKEX: 2616) today announced that the company released the pre-clinical data of its three pipeline products, i.e. CS1001 (anti-PD-L1 monoclonal antibody), CS3002 (CDK4/6 selective small molecule inhibitor) and CS3003 (HDAC6 selective small molecule inhibitor), in the … WebMOBVISTA INC. : Vorstellung des Unternehmens MOBVISTA INC., Aktionäre, Vorstände und Berufsbeschreibung, Finanzstärkerating, offizielle Mitteilungen, Kontaktdaten ...
WebNov 21, 2024 · CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management …
WebMar 13, 2024 · Their share performances varied on Monday, with Broncus Holding Corporation advancing 4% while CStone Pharmaceuticals was down 2.2%. Further supporting sentiment, China reported unexpectedly strong credit growth for February, with money supply expanding at the fastest pace in nearly 7 years, as Beijing looked to … dymocks bathurstWebCStone Pharmaceuticals Aktie 20 Jahre Umsatz, Dividende, Realtime-Kurs, EBIT, Gewinn, Ausschüttungsquote, Nettoverschuldung und die besten Aktienanalysen. ... CStone Pharmaceuticals schüttet eine Dividende von NaN über undefined Auschüttungen im … crystal slots casinoWebDec 21, 2024 · SUZHOU, China, Dec. 21, 2024 /PRNewswire/ -- CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China has approved the new drug application ("NDA") of anti-PD-L1 monoclonal antibody Cejemly ® (sugemalimab) in combination with … dymocks back to school vouchersWebCSTONE PHARMACEUTICALS REGISTERED AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie CStone Pharmaceuticals Registered Shs Unitary Reg S-144A … dymocks books chatswoodWebCStone Pharmaceuticals (HKEX: 2616), a leading biopharmaceutical company focusing on the research, development and commercialization of innovative immuno-oncology … crystals locationscrystal slusherWebSuzhou, China, March 20th, 2024--CStone Pharmaceuticals (HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology ther... 15 2024-03. CStone Pharmaceuticals Reports 2024 Annual Results and Business Updates . crystal slots casino review